- Chambers ranked Doug as a leading lawyer for U.S. Corporate/M&A law (multiple years from 2006 – 2020)
- Law360 named Doug “Tech MVP of the Year” (2019)
- The Deal named him “Lawyer of the Year” for technology and telecom dealmaking (2018)
Ranked among the nation's leading M&A lawyers, Doug has advised companies on more than $175 billion in mergers, acquisitions and divestitures.
Doug advises technology and life sciences clients on mergers and acquisitions, strategic and commercial transactions, corporate counseling and governance, securities matters, shareholder activism and takeover defense. He co-chairs Fenwick’s M&A practice and served as a member of the firm’s executive committee for 10 years.
Doug's transactional experience spans over 25 years and includes over $175 billion of completed mergers, acquisitions and divestitures including cross-border transactions in the software, cybersecurity, internet, life sciences, medical devices, telecommunications, networking, semiconductor, computer hardware and consumer products industries.
Doug is ranked by Chambers Global as among the world’s leading lawyers for U.S. Corporate/M&A and is recognized as a Notable Practitioner for Corporate/M&A in the Nationwide–Highly Regarded listings. The publication, which includes client testimonials, recognized him as:
Doug has served as director of Intergovernmental Relations for the New York City Planning Commission. He has also lectured on transactional law at Columbia University Law School, Stanford University Law School and the Stanford Graduate School of Business.
Over 125 deals for Cisco Systems, including the acquisitions of:
· Scientific-Atlanta for $6.9B
· NDS Group for $5B
· AppDynamics for $3.7B
· WebEx Communications for $3.2B
· Starent Networks for $2.9B
· Sourcefire for $2.7B
· Duo Security for $2.3B
· BroadSoft for $1.9B
Multiple deals for Symantec, including:
· Sale of its Enterprise Security business to Broadcom for $10.7B
· Sale of the Veritas information management business to The Carlyle Group for $7.4B
· Merger with Blue Coat for $4.65B
· Acquisition of LifeLock for $2.3B
· Sale of the website security solutions business to DigiCert for ~$1B
Other transactions:
· VeriSign's $21B merger with Network Solutions
· Concur’s $8.3B acquisition by SAP
· GitHub's $7.5B acquisition by Microsoft
· Excite's $7.2B merger with @Home
· NetScreen Technologies' $4.3B merger with Juniper Networks
· Macromedia's $3.4B merger with Adobe Systems
· Fitbit's pending $2.1B acquisition by Google
· ArcSight’s $1.5B acquisition by Hewlett-Packard
· Elantec Semiconductor's $1.4B acquisition by Intersil
Over 125 deals for Cisco Systems, including the acquisitions of:
· Scientific-Atlanta for $6.9B
· NDS Group for $5B
· AppDynamics for $3.7B
· WebEx Communications for $3.2B
· Starent Networks for $2.9B
· Sourcefire for $2.7B
· Duo Security for $2.3B
· BroadSoft for $1.9B
Multiple deals for Symantec, including:
· Sale of its Enterprise Security business to Broadcom for $10.7B
· Sale of the Veritas information management business to The Carlyle Group for $7.4B
· Merger with Blue Coat for $4.65B
· Acquisition of LifeLock for $2.3B
· Sale of the website security solutions business to DigiCert for ~$1B
Other transactions:
· VeriSign's $21B merger with Network Solutions
· Concur’s $8.3B acquisition by SAP
· GitHub's $7.5B acquisition by Microsoft
· Excite's $7.2B merger with @Home
· NetScreen Technologies' $4.3B merger with Juniper Networks
· Macromedia's $3.4B merger with Adobe Systems
· Fitbit's pending $2.1B acquisition by Google
· ArcSight’s $1.5B acquisition by Hewlett-Packard
· Elantec Semiconductor's $1.4B acquisition by Intersil
· Loxo Oncology’s $8B acquisition by Eli Lilly
· Cepheid’s $4B acquisition by Danaher
· Audentes Therapeutics’ $3B acquisition by Astellas Pharma
· Agilent Technologies’ $1.5B acquisition of Varian
· Dermira’s $1.1B acquisition by Eli Lilly
· Connetics' $930M merger with Stiefel Laboratories
· Loxo Oncology’s $8B acquisition by Eli Lilly
· Cepheid’s $4B acquisition by Danaher
· Audentes Therapeutics’ $3B acquisition by Astellas Pharma
· Agilent Technologies’ $1.5B acquisition of Varian
· Dermira’s $1.1B acquisition by Eli Lilly
· Connetics' $930M merger with Stiefel Laboratories
“Department co-chair Douglas Cogen is a ‘fantastic’ lawyer who routinely handles sophisticated M&A transactions and divestitures on behalf of clients in the technology space. One source appreciates that ‘He is so smart and helps me understand the legal aspect of a matter without the jargon.’”
—Chambers USA
2019 Edition
"He provides outstanding M&A counsel. He's strategic, knowledgeable and has a good bedside manner during an incredibly stressful process."
Chambers USA
2022 Edition
"He provides outstanding M&A counsel. He's strategic, knowledgeable and has a good bedside manner during an incredibly stressful process."
Chambers USA
2022 Edition
Recognition Recognition Recognition
Recognition Recognition Recognition
2024
"MVP of the Year" for Life Sciences
2021
Recognized Doug as one of the 500 Leading Dealmakers in America.
2006-2021
Ranked Doug as a leading lawyer for U.S. Corporate/M&A law (multiple years)
2024
Leading M&A counsel
2021 - 2022
500 Leading Dealmakers in America
2019
Named Doug “Tech MVP of the Year”
2018
Named him “Lawyer of the Year” for technology and telecom dealmaking (2018)
2006, 2013, 2018
Top 100 Attorneys in California